ALK forecasts lower growth in 2023 than strong 2022 result
The allergy firm thinks 7–11% growth in 2023 is likely after a strong 2022 performance meets an upgraded guidance from the summer.
by albert rønning-andersson, translated by daniel pedersen
Allergy firm ALK has concluded fiscal 2022 with strong figures – however, 2023 expectations are still a little dimmer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New ALK head of communications to draw in new hires
For subscribers
ALK loses R&D exec, finds Novo Nordisk replacement
For subscribers
.jpg&w=384&q=75)
